Diarrhea Clinical Trial
Official title:
Characterization Of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
Although the existing diarrhoeagenic Escherichia coli (E. coli) challenge model is already suitable for dietary interventions in its current form, further characterization of the working-mechanism of the attenuated strain and further optimization of the study design will enable the investigators to better select those ingredients that affect the key pathophysiological processes. The aim of the CORAL study is to further characterize and increase the discriminative power of the diarrhoeagenic E. coli challenge model.
Primary Objective:
In the CORAL study the investigators want to determine whether increasing the inoculation
dose of diarrhoeagenic Escherichia coli (E. coli) to 5E10 Colony Forming Units (CFU) (at day
14) and addition of a second challenge 1E10 CFU (at day 35) will result in an increased
effect-size and duration of measurable outcomes and in an expansion of the relevant clinical
and biomarker readouts of the challenge model.
Secondary Objective:
By extensive biomarker and transcriptome analysis of blood and fecal samples, the
investigators aim to explore the working mechanism of the non-toxin producing diarrhoeagenic
E. coli strain and the kinetics of the host response to this infection. In addition, the
investigators want to determine whether adding extended fasting and addition of a
standardized evening meal, prior to the inoculation day, will result in a decreased
between-subject variation.
Study design:
The CORAL study is a parallel 7-weeks intervention study. Subjects will be randomly assigned
to one of two inoculation dosages of a live attenuated diarrhoeagenic E. coli (n=20 per
group). Subjects will be instructed to maintain their usual pattern of physical activity and
their habitual food intake, but to standardize their dietary calcium intake. After a
standardized evening meal and an overnight fast, subjects will be orally infected with a
live, but attenuated, diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food
research; dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22) at study day 14). At study
day 35, after a standardized evening meal and an overnight fast, all subjects will receive a
second inoculation of 1E10 CFU of the ETEC vaccine (n=44).
At various time points before and after both diarrhoeagenic E. coli challenges an online
diary will be kept to record all food and drinks consumption to assess dietary macronutrient
intake. Moreover, subjects will report information on stool consistency, frequency and
severity of symptoms. At various time points before and after both diarrhoeagenic E. coli
challenges venous blood and (complete) stool samples will be collected. Blood and fecal
samples are collected to quantify several infection- and immune system markers.
Study population:
Healthy male subjects, 18-55 years of age who fulfil all of the inclusion criteria and none
of the exclusion criteria will participate in the CORAL study.
Intervention:
At study day 14 and 35, after a standardized evening meal and an overnight fast, all
subjects will receive an inoculation of the diarrhoeagenic E. coli (1E10 CFU (n=22) or 5E10
CFU (n=22) at study day 14; 1E10 CFU (n=40) at study day 35) Subjects will be instructed to
maintain their habitual diet, except for their dairy intake. Dairy has a high calcium
content and contributes significantly to total daily calcium intake. These dietary
guidelines will limit calcium intake on average to 500 mg/day. From our previous studies, we
know that calcium can significantly reduce the gastro-intestinal symptoms induced by the E.
coli strain.
Main study parameter:
1. Percentage of faecal dry weight (% determined by freeze-drying)
Secondary study parameters:
1. Total faecal wet weight (faecal weight in g/day)
2. Time to first diarrhoeal stool (reported by the subjects in the online diary)
3. Stool consistency (Bristol Stool Scale reported by the subjects in the online diary
4. Number of stools with Bristol Stool Scale >4 (Bristol Stool Scale reported by the
subjects in the online diary)
5. Stool frequency (Stools per day reported by the subjects in the online diary)
6. Incidence and duration of WHO-defined diarrhoea (Calculated from the Bristol Stool
Scale and the Stool frequency reported by the subjects in the online diary)
7. The incidence, duration and severity of Gastro-intestinal symptoms (Gastro-intestinal
Symptom Rating Scale reported by the subjects in the online diary).
8. In addition, the study contains an explorative phase consisting of biomarker and
transcriptome analysis, in order to further explore and identify the mechanism and
kinetics of the host response to the infection.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06283784 -
Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients
|
N/A | |
Recruiting |
NCT03851835 -
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
|
Phase 3 | |
Completed |
NCT04003181 -
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
|
N/A | |
Completed |
NCT03596827 -
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
|
N/A | |
Recruiting |
NCT05372068 -
Cement flooRs AnD chiLd hEalth (CRADLE)
|
N/A | |
Completed |
NCT03972618 -
Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT05052489 -
Registry and Clinical Observation of Children With Diarrhoeal Disease
|
||
Completed |
NCT02428647 -
Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT01739231 -
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01968408 -
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
|
Phase 3 | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Not yet recruiting |
NCT01382199 -
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
|
Phase 3 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Terminated |
NCT01472211 -
Water-based Zinc Intervention Trial in Zinc Deficient Children
|
Phase 0 | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT00760851 -
Yogurt Study in Children 2-4 Years Old Attending Daycare
|
Phase 3 | |
Completed |
NCT00198796 -
Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains
|
Phase 1 |